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Abstract: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has alarmed
the world since its first emergence. As pregnancy is characterized by significant changes in cardiovascular, respiratory, endocrine, and
immunological systems, there are concerns on issues like the course of disease in pregnant women, safety of medications, route of
delivery and risk of obstetric complications. The aim of this review is to summarize the current literature in the management of pregnant
women during the COVID-19 pandemic. Although more than 90% of pregnant women with COVID-19 recover without serious
morbidity, rapid deterioration of disease and higher rates of obstetric complications may be observed. The risk of vertical transmission
has not been clearly revealed yet. Decreasing the number of prenatal visits, shortening the time allocated for the examinations, active
use of telemedicine services, limiting the number of persons in healthcare settings, combining prenatal tests in the same visit, restricting
visitors during the visits, providing a safe environment in healthcare facilities, strict hygiene control, and providing personal protective
equipment during the visits are the main strategies to control the spread of disease according to current guidelines. Although new
medication alternatives are being proposed every day for the treatment of COVID-19, our knowledge about the use of most of these drugs
in pregnancy is limited. Preliminary results are promising for the administration of SARS-CoV-2 vaccines in the pregnant population.
Timing of delivery should be decided based on maternal health condition, accompanying obstetric complications and gestational age.
Cesarean delivery should be performed for obstetric indications. Breast feeding should be encouraged as long as necessary precautions
for viral transmission are taken. In conclusion, an individualized approach should be provided by a multidisciplinary team for the
management of pregnant women with COVID-19 to achieve favorable outcomes.
Key words: COVID-19, obstetric complications, pregnancy, SARS-CoV-2, vaccines

1. Introduction
Coronavirus disease 2019 (COVID-19) caused by severe
acute respiratory syndrome coronavirus 2 (SARSCoV-2) has alarmed the world since its first emergence
[1]. It significantly changed people’s daily routines,
forcing countries to make comprehensive regulations.
Social isolation, strict hygiene control, remote working,
lockdown, and comprehensive immunization programs
are the main strategies to control the pandemic in this
extraordinary period [2]. However, it has been more than
a year since the beginning of the pandemic and the disease
has not been fully controlled yet. During this period,
healthcare professionals made a superhuman effort and
unfortunately some of them lost their lives during this
tough process [3].

Like other branches of medicine, obstetrics have been
also affected by the pandemic. During this period, health
authorities had to make some important regulations to
protect mothers, babies, and healthcare professionals from
COVID-19 [4]. Reducing the number of antenatal visits,
encouraging telemedicine services, combining routine
screening tests in the same session, and providing adequate
personal protective equipment are some of the methods to
control the spread of infection during the pandemic [4].
As pregnancy is characterized by significant changes in
cardiovascular, respiratory, endocrine, and immunological
systems, there are concerns on issues like the course
of disease in pregnant women, safety of medications,
route of delivery and risk of obstetric complications [5].
Our experience on these issues is increasing day by day
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and management guides are regularly updated in this
context1,2,3.
The aim of this review is to summarize the current
literature in the management of pregnant women during
the COVID-19 pandemic.
2. Epidemiology and virology
At the end of 2019, a series of pneumonia cases were
reported in Wuhan, a city in the Hubei Province of China.
Investigations revealed a novel coronavirus responsible
for the mentioned infection and it rapidly spread all over
the globe resulting in a pandemic [6]. Since its emergence,
SARS-CoV-2 has infected millions of people leading to
significant morbidity and mortality [6].
Coronaviruses are enveloped positive-stranded RNA
viruses. SARS-C0V-2 is a betacoronavirus sharing the
same subgenus with the severe acute respiratory syndrome
(SARS) and the Middle East respiratory syndrome
(MERS) viruses [7]. It enters the host cell via angiotensinconverting enzyme 2 (ACE2) receptor. SARS-CoV-2 binds
to ACE2 receptor with its spike protein and the cellular
protease transmembrane protease, serine 2 (TMPRSS2) has
a significant role in this process [8]. Several mutations in
the genome of SARS-CoV-2 have been observed since the
beginning of the pandemic. The mutations mainly resulted
in a functional change in the spike protein. Although most
of them have no clinical significance, some of them have
a potential to rapidly infect a great number of cases [9].
The most popular defined variants are B.1.1.7 lineage (first
identified in the United Kingdom), B.1.351 lineage (first
identified in South Africa), P.1 lineage (first identified
in Japan in four travelers from Brazil), B.1.427/ B.1.429
lineages (first identified in the Southern California) and
B.1.617 lineage (first identified in India) [10].
3. Prevention
The main mode of SARS-CoV-2 transmission is close
person-to-person contact. Respiratory secretions are
considered the source of viral transmission, and inhalation
of viral particles or contact with mucous membranes cause
transmission of infection [11]. SARS-CoV-2 is also detected
in stool, blood, ocular secretion, and semen samples.
However, their roles in the transmission of disease are
uncertain [12]. The risk of transmission starts even in the
asymptomatic period and it is highest in the earlier days of
the disease. The risk of transmission significantly decreases
after 7 to 10 days of illness [13]. Viral load, duration of

contact, and use of personal protective equipment are all
important factors for the risk of transmission [14].
The main strategy for controlling the spread of
COVID-19 is preventing close contact with an infected
individual. For this reason, social distancing, remote
working, establishment of telehealth services, application
of distance learning programs, lockdown, strict hygiene
control, screening high-risk populations, administration
of filiation programs, self-quarantine and providing
broad-based use of personal protective equipment have
been widely used by governments during the pandemic
[15].
Pregnant women should also pursue the mentioned lifestyle changes in order to reduce the risk of transmission.
They should effectively use personal protective equipment
and special care should be taken for pregnant women
with children in the home. Working conditions should
be arranged according to underlying comorbidities and
workplace environment [4,16].
There are other issues in the prevention of disease like
vaccination and pre-/postexposure prophylaxis [17,18].
However, the efficacy of pre-/postexposure prophylaxis
has not been proven yet, and the safety of vaccines in
pregnant women is still under investigation [18,19]. The
role of vaccination in pregnant women will be discussed in
detail later in the present review.
Another important problem is the reproductive
decision-making during the pandemic period. Although
the course of COVID-19 seems to be worse in pregnant
women, the potential pregnancy-related risks associated
with SARS-CoV-2 have not been fully clarified yet [20].
Thus, pregnancy can be planned by taking necessary
precautions.
4. Clinical findings
Clinical findings in pregnant women with COVID-19
are similar to those in nonpregnant population [21].
According to the results of a study including 461,825
pregnant women with laboratory-confirmed infection, the
most common symptoms were: cough (50.3%), headache
(42.7%), muscle aches (36.7%), fever (32.0%), sore throat
(28.4%), shortness of breath (25.9%), and loss of taste
or smell (21.5%) [21]. A preliminary study including 29
confirmed and 71 clinically suspected pregnant women
with COVID-19 from Turkey reported cough (58.6%) and
myalgia (51.7%) as the leading symptoms [22]. Updated
version of the mentioned study including 533 confirmed

Coronavirus infection and pregnancy Version 7 2020: updated 09/04/2020. Website https://www.rcog.org.uk/coronavirus-pregnancy [accessed on 31
May 2021]
1

ACOG. Novel Coronavirus 2019: updated 1.5.2021. Website https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/03/novelcoronavirus-2019 [ accessed on 31 May 2021]
2

Turkish Ministry of Health, General Directorate of Public Health, COVİD-19 Guideline, Scientific Committee Report: updated 21.08.2020. https://
covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf?type=file [accessed on 31 May 2021]
3

3313

ŞAHİN et al. / Turk J Med Sci
cases reported cough (33.4%) and myalgia (31.5%) as the
leading symptoms again [23]. Nausea, vomiting, fatigue,
diarrhea, and rhinorrhea may also accompany COVID-19
to a lesser extend [21–23].
The rate of asymptomatic cases was investigated in
various studies [24–26]. A prospective study from Turkey
including 206 pregnant women (103 low-risk pregnant
women without any defined risk factor and 103 highrisk pregnant women) reported positive real-time reverse
transcriptase polymerase chain reaction (RT-PCR) results
in 3 cases (1.4%). All of them were in the high-risk
pregnancy group [24]. A systematic review including 77
studies performed on 11,432 pregnant women reported a
positivity rate of 7% in the universal screening and 73%
of them were asymptomatic. Additionally, the mentioned
study claimed that pregnant women were more likely to be
asymptomatic than nonpregnant people of reproductive
age with COVID-19 [25]. Another systematic review
revealed that 95% of pregnant women with COVID-19
were asymptomatic [26].
5. Radiologic imaging and laboratory findings
Like other viral pathogens SARS-CoV-2 may cause
increased levels of acute phase reactants, leukocyte count,
and liver enzymes together with decreased levels of
lymphocyte and platelet counts. According to the results
of a systematic review, increased C-reactive protein
(CRP) levels (49%), lymphopenia (33%), leukocytosis
(26%), elevated procalcitonin levels (23%), abnormal liver
enzymes (15.4%), and thrombocytopenia (6.6%) were the
most common laboratory findings [28]. Lymphopenia
(30.4%), anemia (8.4%), elevated liver enzymes (4.5%),
and hypokalemia (1.5%) were the most significant findings
in a comprehensive study from Turkey [23].
According to the results of a systematic review
including 427 pregnant women with COVID-19, groundglass opacities (77%), posterior lung involvement (73%),
multilobar involvement (72%), bilateral lung involvement
(69%), peripheral distribution (68%), and consolidation
(41%) were the most common pathologic findings in the
computerized tomography (CT) [27]. Radiologic imaging
was performed in 12.7% of the pregnant women, and
57.3% of them were suspicious for COVID-19 according
to the results of a prospective study from Turkey [23].
Physicians should keep in mind that physiological
changes during pregnancy and sometimes pregnancy
complications like preeclampsia may also cause alterations
in laboratory tests. Thus, individualized approach should
be applied for all cases and every pregnant woman should
be evaluated rigorously to provide optimal healthcare.
Another important factor is the concern of pregnant

women for possible adverse effects of radiation on their
babies. However, it has been long known that a radiation
dose less than 0.05 gray has no known adverse effect on the
growing fetus and chest imaging may be performed safely
providing abdominopelvic protection [28]. Furthermore,
lung ultrasonography is a safer alternative in selected cases.
Thickening of the pleural line with pleural line irregularity,
focal, multifocal, confluent B lines, consolidations, air
bronchograms, pleural effusion, and appearance of A
lines during recovery phase may indicate COVID-19
pneumonia [29]. In our opinion, these procedures may be
performed effectively and safely in experienced centers.
6. COVID-19 severity classification
There are several classifications in clinical use for the
assessment of disease severity [30,31]. These classifications
were developed for the evaluation of nonpregnant adult
patients. However, they can be used in the pregnant
population, too. The National Institutes of Health (NIH)
classification is used in the United States [30]. It divides the
disease into 5 groups: asymptomatic or presymptomatic
infection, mild illness, moderate illness, severe illness,
and critical illness according to the clinical findings [30].
Another classification from China categorizes patients
into 3 groups: mild, severe, and critical [31]. According to
the national guideline by the Turkish Ministry of Health,
General Directorate of Public Health, patients are divided
into 4 categories: uncomplicated cases, cases with mild/
moderate pneumonia, cases with severe pneumonia, and
critical cases that may necessitate intensive care unit (ICU)
admission4. The mentioned classifications are summarized
in Table 1.
7. Course of COVID-19 in pregnancy
Current literature indicates that pregnancy does not
increase the risk of acquiring COVID-19 but the course of
disease seems to be worse in pregnant women compared
to nonpregnant females of the same age [21,25,32–34].
Although more than 90% of pregnant women with
COVID-19 recover without serious morbidity, rapid
deterioration of disease may be observed. Especially
symptomatic pregnant women have a higher risk for severe
disease compared to the symptomatic nonpregnant women
with COVID-19. Severe disease is more common in cases
with coexisting comorbidities like obesity, asthma, older
maternal age, hypertension, and diabetes [21,25,32–34].
Maternal death rates range between 0.14 and 0.80. However,
due to the relatively low number of maternal mortality cases
and the possible underestimation of asymptomatic cases,
these rates may be deceptive [21,25,32–34]. According to
the results of a report from the Centers for Disease Control

Turkish Ministry of Health, General Directorate of Public Health, COVID-19 Guideline, Scientific Committee Report: updated 21.08.2020. https://
covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf?type=file [accessed on 31 May 2021]
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Table 1. Classifications for disease severity.
The National Institutes of Health (NIH) classification
1) Asymptomatic or presymptomatic infection

Positive test for SARS-CoV-2 but no symptoms

2) Mild illness

Any signs and symptoms (e.g., fever, cough, sore throat, malaise, headache, muscle
pain) without shortness of breath, dyspnea, or abnormal chest imaging

3) Moderate illness

Evidence of lower respiratory disease by clinical assessment or imaging and a
saturation of oxygen (SaO2) ≥ 94% on room air at sea level

4) Severe illness

Respiratory frequency >30 breaths per minute, SaO2 < 94% on room air at sea level,
ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/
FiO2) < 300, or lung infiltrates > 50%

5) Critical illness

Respiratory failure, septic shock, and/or multiple organ dysfunction

Wu classification
1) Mild illness

No or mild symptoms (fever, fatigue, cough, and/or less common features of
COVID-19)

2) Severe illness

Tachypnea (respiratory rate >30 breaths per minute), hypoxia (oxygen saturation
≤ 93% on room air or PaO2/FiO2 < 300 mmHg), or >50% lung involvement on
imaging)

3) Critical illness

Cases with severe clinical features like respiratory failure, shock, or multiorgan
dysfunction

The National Guideline by Turkish Ministry of Health, General Directorate of Public Health
1) Uncomplicated cases

a) Symptoms such as fever, muscle/joint pain, cough, sore throat, and respiration
without distress (respiratory rate < 24, SpO2 > 93% on room air)
AND
b) Patients with normal chest X-ray and/or lung tomography

2) Cases with mild/moderate pneumonia

a) Symptoms such as fever, muscle/joint pain, cough and sore throat, respiratory
rate < 30/min, SpO2 > 90% on room air
AND
b) Mild-to-moderate pneumonia in chest radiography or tomography

3) Cases with severe pneumonia

a) Symptoms such as fever, muscle/joint pain, cough and sore throat, tachypnea (30/
min), SpO2 below 90% on room air
AND
b) Bilateral diffuse pneumonia finding on chest radiography or tomography

4) Critical cases that may necessitate intensive
care unit admission

Cases with at least one of the following clinical findings:
a) Dyspnea and respiratory distress
b) Respiratory rate ≥ 30/min
c) PaO2/FiO2 < 300
d) SpO2 < 90% or PaO2 < 70 mmHg despite 5 L/min oxygen therapy
e) Hypotension (systolic blood pressure < 90 mmHg and 40 mmHg from usual SBP
and mean arterial pressure < 65 mmHg, tachycardia > 100/min
f) Acute kidney injury, abnormal liver function test, development of acute
organ dysfunction such as confusion, acute bleeding diathesis, and patients with
immunosuppression
g) High troponin levels and arrhythmia
h) Lactate > 2 mmol
i) Skin disorders such as capillary return disorder and cutis marmaratus

COVID-19: Coronavirus disease 2019, SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
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and Prevention (CDC) including more than 23,000
pregnant women and over 386,000 nonpregnant females of
reproductive age with symptomatic laboratory-confirmed
SARS-CoV-2 infection, pregnant women with COVID-19
had higher risk for ICU admission, invasive ventilation,
extracorporeal membrane oxygenation (ECMO), and
mortality [25]. Another prospective study comparing 5183
pregnant women with 175,905 nonpregnant ones reported
that pregnant women with COVID-19 had higher rates of
mortality, pneumonia, and ICU admission [35].
8. Vertical transmission
The risk of vertical transmission has not been clearly
revealed yet. According to a systematic review including
neonates born to 936 infected pregnant women, neonatal
PCR positivity was observed in 2.9% of the cases. In the same
study, 1/34 cord blood samples and 2/26 placental samples
were also positive for SARS-CoV-2. Finally, 3/82 neonatal
serologies were immunoglobulin M (IgM)-positive for
SARS-CoV-2 [36]. In utero transmission may occur by
hematogenous or ascending route [37]. The theoretical
risk for placental infection seems to be low since the
coexpression of ACE-2 receptor and TMPRSS2 is minimal
in the placental tissue [38]. However, SARS-CoV-2 can
infect the placenta causing some histopathological changes
[39]. This can be a contributing factor for COVID-19–
related pregnancy complications. Another study from
Turkey investigated the risk of maternal-fetal transmission
in the early pregnancy and found no evidence of SARS
CoV-2 infection in the fetal-placental samples [40]. The
definitive diagnosis of congenital infection can only be
made by the detection of SARS-CoV-2 RT-PCR positivity
in umbilical cord blood or neonatal blood collected within
the first 12 h of birth or amniotic fluid collected prior to
rupture of membranes [41]. Transmission of SARS-CoV-2
can also occur in the intrapartum/postpartum period [42].
Thus, management of delivery and breastfeeding should be
managed according to strict protocols in order to protect
the neonates from the infection [23].
9. Obstetric and neonatal complications
According to the literature, COVID-19 may be associated
with obstetric complications like preterm delivery, fetal
distress and increased cesarean section rates [23,25,34,43–
47]. It has been long known that excessive inflammation,
hypoxia, maternal fever and worsening in maternal health
condition may trigger premature labor and may cause fetal
distress. However, obstetric complications may also occur
in mild COVID-19 cases and more data is necessary to
reach a clear conclusion. Moreover, most of the mentioned
studies did not report iatrogenic prematurity rates. For this
reason, information related to fetal distress and preterm
delivery may be misleading [23,25,34,43–47]. Current

3316

data from the United States indicated an overall preterm
delivery rate of 7.2% in pregnant women with COVID-19
compared to the ratio of 5.8% in pregnant women without
COVID-19. However, the overall cesarean section rate was
similar between the groups [48]. A current populationbased study from England reported higher rates of fetal
death and preterm delivery in patients with SARS-CoV-2
infection compared to pregnant women without SARSCoV-2 infection. Furthermore, this study also reported
increased risks for preeclampsia/eclampsia, emergency
cesarean section, prolonged hospital admission after
delivery, neonatal adverse outcome, and neonatal
readmission in SARS-CoV-2 positive pregnant women
[33].
The risk of miscarriage in pregnant women with
COVID-19 is controversial. There is no direct evidence for
increased miscarriage rates in infected pregnant women.
On the other hand, there are concerns related to the
possible risk of miscarriage especially in severe/critical
cases [23,49–51]. Another important topic is the risk of
congenital anomalies in pregnant women with COVID-19.
However, no direct association has been reported between
SARS-CoV-2 infection and increased rate of congenital
anomalies for the time being [52–54]. Although overall
stillbirth rate seems to be similar between SARS-CoV-2
positive and negative cases, an increased rate was reported
for hospitalized patients [55,56].
Neonatal outcomes were generally favorable and
more than 95% of the newborns were healthy according
to the literature [25,57–60]. Majority of the neonates
born to mothers with COVID-19 were asymptomatic.
Symptomatic ones had symptoms of mild infection that
did not require respiratory support [25,57–60]. The
main reason behind the neonatal morbidity in infected
pregnant women was prematurity most probably due to
the increased rates of preterm deliveries performed severe
COVID-19 [25,57–60].
According to the findings of a study from Turkey,
12.4% of the pregnant women with COVID-19 had
pregnancy complications. Preterm delivery followed
by miscarriage was the most common one. No cases of
vertical transmission were observed in the mentioned
study and neonatal intensive care unit (NICU) admission
rate was 9.9% [23]. The roles of various cytokines,
vitamins, mediators and trace elements on clinical
outcomes were investigated in novel studies [61–64]. These
studies indicated that the impact of disease on perinatal
outcomes was associated with complex biological events
and appropriate supplementation of some nutrients may
improve the course of COVID-19 in selected cases [61–
63].
The possible effect of COVID-19 on fetal Doppler
parameters was also investigated in current studies [65,66].
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No difference was present between healthy pregnant
women and those with mild/moderate COVID-19 in
terms of fetal Doppler parameters [66]. However, the
pulsatility and resistance indices of umbilical and uterine
arteries showed a significant increase in pregnant women
recovered from COVID-19 compared to the controls [65].
The possible adverse effect of COVID-19 on the fetoplacental circulation may be one of the factors behind the
increased rates of perinatal complications in these cases.
Another important topic is the effect of disease
severity on obstetric complications [67–69]. These studies
indicated that severe/critical disease was associated with
increased rates of preterm and cesarean deliveries mostly
due to the worsening in maternal health condition [67,68].
Moreover, a higher rate of obstetric complications was
observed in cases with higher viral load [69].
10. Diagnosis
Nucleic acid amplification testing to detect SARS-CoV-2
RNA from the upper respiratory tract of the individuals
is the most commonly used method for the definitive
diagnosis of COVID-19 [70]. RT-PCR analysis of a
nasopharyngeal swab specimen is the standard technique
in Turkey [24]. A positive test confirms the diagnosis with
a false negative rate ranging from 5% to 40%. A repeat test
is recommended in cases with high clinical suspicion 24
to 48 h after the initial test. Lower respiratory specimens
have higher sensitivity [71]. Although it is less sensitive
than the nucleic acid amplification testing, antigen testing
for SARS-CoV-2 may be preferred in selected cases with
a rapid result [72]. Serologic testing may be used in the
determination of previous SARS-CoV-2 infection or
current infection with positive symptoms for 3 to 4
weeks [73]. Screening for clinical findings of COVID-19
should be performed in all patients admitted to a healthcare facility. Performing a diagnostic test for all cases
admitted to delivery may be considered according to the
infrastructure of the hospitals. Special attention should
be paid to differentiate COVID-19 from other respiratory
pathogens and obstetric complications like preeclampsia
with severe features5.
11. Prenatal care
International organizations like The American College of
Obstetricians and Gynecologists (ACOG), Royal College
of Obstetrics and Gynecologists (RCOG), and the Society
for Maternal-Fetal Medicine (SMFM) established their
guidelines for the management of prenatal care during
the COVID-19 pandemic [74]. Their recommendations
mostly focus on decreasing the number of prenatal visits
and shortening the time allocated for the examinations.

Dividing the patients into two categories: low- versus
high-risk patients (multiple gestation, hypertension,
diabetes etc.) and decreasing the number of visits for
low-risk population seem to be reasonable, active use of
telemedicine services, limiting the number of persons in
health-care settings, combining prenatal tests in the same
visit, restricting visitors during the visits, providing a safe
environment in healthcare facilities, strict hygiene control,
and providing personal protective equipment during
the visits are the main strategies to control the spread
of disease according to current guidelines. Preferring
75 g 2-h oral glucose tolerance test and recommending
cell-free DNA screening may help physicians to reduce
the number of visits. Routine antenatal prophylactic
corticosteroid therapy is recommended in cases with
increased risk of preterm delivery. Low-dose aspirin (81
to 150 mg/day) can be administered safely in cases at high
risk for preeclampsia. Patients with previous history of
preeclampsia, multifetal gestation, chronic hypertension,
diabetes mellitus, chronic kidney disease, obesity, or
autoimmune disease with potential vascular complications
have higher risk for developing preeclampsia. Low-dose
aspirin for preeclampsia prevention should be initiated at
≥12 weeks of gestation, and ideally prior to 16 weeks in
clinically indicated cases. The treatment can be continued
until 36 weeks of gestation or 5 to 10 days before expected
delivery time to decrease the risk of excessive postpartum
bleeding [75]. Although there are some publications in
the literature reporting increased risk of preeclampsia in
pregnant women with COVID-19 routine administration
of prophylactic aspirin is not recommended. Thus,
clinicians should decide on the therapy based on clinical
characteristics of the individuals [76]. The application
of tocolysis is controversial and generally it is not
recommended to delay delivery to administer antenatal
steroids. Magnesium sulfate may be administered for
the prophylaxis of eclampsia although it has a potential
to cause respiratory muscle weakness. Prenatal invasive
diagnostic tests may be performed if indicated [74].
Clinicians should also provide appropriate psychiatric
support for the patients in this extraordinary period [77].
12. Hospitalization
Patients with progressive dyspnea, fever >39 °C despite
antipyretics, intolerance for medications, persistent chest
pain, confusion, obstetric complications, respiratory rate
≥20–24 /min, and/or heart rate >100 beats/min should be
followed up in the hospital settings. Maternal peripheral
oxygen saturation (SpO2) should be maintained at ≥95%
[78]. Inpatient care indications are summarized in Table 2.

Coronavirus infection and pregnancy Version 7 2020: updated 09/04/2020. Website https://www.rcog.org.uk/coronavirus-pregnancy [accessed on 31
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Table 2. Inpatient care indications for pregnant women with COVID-19.
Presence of a comorbidity or obstetric complication (active uterine bleeding, preeclampsia, prelabor rupture of membranes, poor
glycemic control in diabetic patients, uncontrolled hypertension etc.)
Fever > 39 °C despite use of acetaminophen
Moderate/severe symptoms (oxygen saturation < 95% on room air, respiratory rate > 30/min, rapidly increasing need for
supplemental oxygen)
Critical COVID-19 (Respiratory failure, hypotension despite appropriate hydration, and/or new end-organ dysfunction)
COVID-19: Coronavirus disease 2019

13. Medical therapy for COVID-19 in pregnant women
New medication alternatives are being proposed every day
for the treatment of COVID-19, and our knowledge about
the use of most of these drugs in pregnancy is limited.
Below we discussed some of the most popular medications
in brief.
13.1. Anticoagulants
The risk of venous thromboembolism was found to be
increased in pregnant women with COVID-19 [48].
Infection with SARS-CoV-2 should be considered a
transient risk factor for venous thromboembolism.
Prophylactic-dose anticoagulation is recommended
for hospitalized patients with severe COVID-19. If
thromboprophylaxis has been started in a self-isolated
patient, it should be continued until recovery from
acute illness (between 7 and 14 days). The optimal dose,
duration, and type of thromboprophylaxis should be
chosen by a multidisciplinary team in severe/critic
cases. Thromboprophylaxis should be continued for 10
days following hospital discharge and longer duration
of thromboprophylaxis may be considered for patients
with serious morbidity. Thromboprophylaxis should be
offered for all pregnant women admitted with confirmed
or suspected COVID-19, unless birth is expected
within 12 h or there is significant risk of hemorrhage.
For women within 6 weeks of their postpartum period,
thromboprophylaxis should be administered for the
duration of their admission and for at least 10 days after
discharge. Thromboprophylaxis may be extended until
6 weeks postpartum in cases with serious morbidity.
Low-molecular-weight heparin (enoxaparin 40 mg
subcutaneously every 24 h) or unfractionated heparin
(5000 units in the first trimester, 7500 to 10,000 units in the
second trimester, and 10,000 units in the third trimester,
administered subcutaneously every 12 h) may be used for
thromboprophylaxis. Laboratory parameters like D-dimer,
ferritin, and CRP may be helpful for the clinicians for
ongoing of anticoagulants after recovery of COVID-19
symptoms on pregnant women6. Intermittent pneumatic

compression may be performed when anticoagulant
therapy is contraindicated [79].
13.2. Glucocorticoids
Dexamethasone 6 mg/day for 10 days or until discharge may
be considered for severe cases that necessitate supplemental
oxygen or ventilatory support. Glucocorticoid therapy
may also be administered in critical cases with refractory
shock. As dexamethasone crosses the placenta, it also has a
favorable effect on fetal lung maturation in preterm labor.
Other steroids like methylprednisolone or hydrocortisone
may be used when less fetal exposure is preferred [80].
13.3. Nonsteroidal antiinflammatory drugs
Nonsteroidal antiinflammatory drugs may cause
unfavorable adverse effects on the fetus like
oligohydramnios, premature closure of the ductus
arteriosus. For this reason, they should be administered
in the lowest dose possible and the treatment should not
be continued more than 48 hours [81]. Acetaminophen is
considered a safe alternative in pregnant patients; however,
there are concerns about its use in cases with elevated liver
enzymes [82].
13.4. Hydroxychloroquine
The immunomodulatory and anti-inflammatory effects
of hydroxychloroquine have long been known. Although
its effect in SARS-CoV-2 infection has not been clearly
identified yet, modification on ACE-2 glycosylation
and increase in the pH of the endosomes are thought
to be the possible mechanisms. However, physicians
should be cautious about the potential risk of ventricular
arrhythmias [83]. Although it crosses the placenta and is
excreted in breast milk, no adverse effect on the fetus has
been observed in the observational studies [84].
13.5. Azithromycin
It is a macrolid antibiotic with potential antiviral,
immunomodulatory, and antiinflammatory characteristics.
Although its role in the treatment of COVID-19 is
questionable, it elevates cellular pH and disrupts the
binding of SARS-CoV-2 with ACE-2 receptors. Moreover,

Coronavirus infection and pregnancy Version 7 2020: updated 09/04/2020. Website https://www.rcog.org.uk/coronavirus-pregnancy [accessed on 31
May 2021]
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it has some immunomodulatory properties which slows
down cytokine storm. However, physicians should be
cautious about the prolongation of the QT interval.
It is regarded as category B for administration during
pregnancy. Initial dose of 500 mg per oral followed by
250 mg per oral daily for 4 days may be administered for
the treatment of COVID-19 [85].
13.6. Lopinavir–ritonavir
This combination drug consists of two antiretroviral
protease inhibitors primarily used for human
immunodeficiency virus (HIV). However, it may be used
for the treatment of SARS-CoV-2 infection although
there are ongoing debates [86]. It is considered category
C for pregnant women and no potential adverse effect was
observed in pregnant women with HIV [87].
13.7. Remdesivir
It is a novel nucleotide analog used for the treatment of
SARS-CoV-2. No fetal toxicity was reported for its use in
Ebola and Marburg viruses [88].
13.8. Favipiravir
It is an antiviral, nucleoside analog that inhibits RNAdependent RNA polymerase. It was mainly used for
oseltamivir-resistant influenza viruses but it is regarded
as a potential medication for SARS-CoV-2 infection
with favorable outcomes. However, there is insufficient
data regarding its use in pregnant and lactating women.
Thus, its application should be avoided in these specific
populations [89].
13.9. Tocilizumab
It is a monoclonal antibody that inhibits IL-6. It has
been mainly used for rheumatologic diseases. As IL-6
is one of the main actors of cytokine release syndrome,
administration of tocilizumab may be beneficial in severe
patients with COVID-19. However, its safety in pregnant
and lactating women is questionable. As it can be excreted
in breast milk, lactation should be avoided in patients
taking this medication [84,87].
13.10. Anakinra
It is an IL-1 receptor antagonist that has a potential to
block the proinflammatory cytokine cascade. Although it
has been primarily used for rheumatologic diseases, some
studies indicated favorable results in COVID-19 cases. It
may be used in pregnant women although our knowledge
is still limited [84,87].
13.11. Convalescent plasma
Although convalescent plasma has been used in
some pregnant women with COVID-19, its efficacy is
controversial. Thus, it is not a routine part of therapy for
pregnant population [90].
13.12. Neutralizing monoclonal antibodies
Combination
of
monoclonal
antibodies
like
Bamlanivimab-etesevimab or casirivimab-imdevimab

may be used for the treatment of SARS-CoV-2 infection.
They can be used in cases with mild/moderate disease
with a potential for rapidly progressing to severe/critical
disease. They have a potential to cross the placenta and
affect the fetus. However, our knowledge is insufficient
regarding their impact on the developing fetus [89].
14. Vaccines
Pregnancy is considered a risk factor for severe COVID-19
by healthcare authorities [6,7]. Thus, protecting pregnant
women from SARS-CoV-2 infection is crucial to decrease
maternal morbidity and mortality. Vaccination seems
to be the most promising method to control the spread
of COVID-19, and there are various vaccine platforms
that have been administered on large populations in the
last months. However, due to the exclusion of pregnant/
lactating women from the preliminary vaccine trials, our
knowledge is limited on the safety and efficacy of vaccines
in these vulnerable populations [91]. Most preapproved
vaccines work by introducing an antigen into the body
to induce an immune response. The antigen can be an
inactivated infectious agent (Sinovac, Sinovac Biotech,
China) or a protein purified from the infectious agent.
In contrast, COVID-19 mRNA vaccines developed
by Pfizer-BioNTech (BNT162b2, Pfizer-BioNTech,
Germany) and Moderna (mRNA-1273, ModernaTX, the
United States) work by carrying the genetic information
required to produce the spike protein of SARS-CoV-2, the
protein found on the virus surface. When the vaccine is
injected into muscle cells, they produce the spike protein
recognized by the immune system, the mRNA never
enters the nucleus and therefore does not integrate into
the DNA; within hours to days, mRNA is degraded in
the cell cytoplasm. Vaccines developed by AstraZeneca–
Oxford (AZD1222, AstraZeneca-Oxford, the United
Kingdom) and Janssen-Johnson and Johnson (Ad26.
COV2.S, Janssen-Johnson and Johnson, the United
States) use a modified viral vector to deliver the spike
protein of SARS-CoV-2 to cells, which then trigger an
immune response. The AstraZeneca-Oxford (AZD1222,
AstraZeneca-Oxford, the United Kingdom) vaccine uses a
nonreplicable modified chimpanzee adenovirus, whereas
the Janssen-Johnson and Johnson vaccine (Ad26.COV2.S,
Janssen-Johnson and Johnson, the United States) uses
Human Adenovirus 26, a nonreplicating modified human
adenovirus. Vaccines developed by Novavax (Novavax,
the United States) and GSK-Sanofi (VAT00008, GSKSanofi, France-the United Kingdom) are protein subunit
vaccines in which a baculovirus is used to produce the
recombinant protein in insect cells. Both of these vaccines
have been mixed with adjuvants to boost the immune
response [92]. As none of the vaccine platforms contains
live viral particles which have a potential to replicate, they
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are considered theoretically safe in pregnancy. However,
adverse events may occur due to altered immune response
[93]. Preliminary data from a limited number of studies
demonstrated no adverse events in vaccinated pregnant
women and they reported transfer of maternal antibodies
across the placenta and into breast milk [94,95]. Among
3958 participants enrolled in the v-safe pregnancy registry,
827 had a completed pregnancy and no prominent
adverse event was reported [94]. Thus, according to
the preliminary data, vaccination may be offered for
pregnant women as they have an increased risk for severe
disease. ACOG recommends vaccination for all eligible
pregnant and lactating women7. Both Turkish Society of
Obstetrics and Gynecology and Maternal-Fetal Medicine
and Perinatology Society of Turkey have recommended
vaccination during pregnancy. They stated that pregnant
women could be vaccinated safely after the first trimester
(14 weeks of pregnancy) with their rappel intervals. Either
inactivated or mRNA vaccine platforms may be preferred
according to mentioned societies8,9.
15. Labor, delivery, and postpartum care of pregnant
women with COVID-19
Timing of delivery should be decided based on maternal
health condition, accompanying obstetric complications
and gestational age [4,23]. For asymptomatic cases and
patients with nonsevere COVID-19, delivery at <39 weeks
of gestation should be avoided unless there is an obstetric
complication that necessitates prompt delivery [4,23]. For
severe/critical cases, an individualized approach should be
preferred. Delivery may be considered at >32–34 weeks of
gestation for severe not intubated cases. The management
of intubated cases should be performed according to
maternal clinical characteristics. Prompt delivery may
be considered in the presence of refractory hypoxemic
respiratory failure or worsening critical illness [4,23].
Strict precautions should be taken to reduce the
risk of viral transmission during delivery. Screening all
patients for clinical manifestations of COVID-19, using
adequate personal protective equipment, providing singleoccupancy rooms with good ventilation and reducing the
number of persons in the delivery room are the primary
steps for the healthcare facilities. Diagnostic tests may be
performed for scheduled labor inductions and cesarean
deliveries. Contact and droplet precautions should be
followed for the delivery of confirmed or highly suspected

cases [4,23]. A novel delivery table shield has been used
during the vaginal delivery of suspected/confirmed cases
in our institution since the early days of the pandemic.
This equipment protects the healthcare professionals
from respiratory droplets during the second stage of labor
allowing eye contact and comfortable respiration for the
mother [96]. The demonstration of the mentioned delivery
table shield is shown in Figure.
Cesarean delivery should be performed for obstetric
indications. However, acute decompensation in critical
cases may also necessitate prompt delivery with cesarean
section [4,23]. Induction of labor may be performed for
intubated patients but follow-up of labor may be difficult
in the ICU settings. Cesarean section may be associated
with an increased risk for clinical worsening but more data
is necessary to achieve more precise results on this issue
[97].
Regional anesthesia is generally recommended in the
delivery of pregnant women with COVID-19 due to its
advantages for both the patient and the healthcare staff.
Use of nitrous oxide is controversial and most of the
authorities recommend not to use it [98].
Continuous
electronic
fetal
monitoring
is
recommended during labor. Although SARS-CoV-2 is
rarely detected in amniotic fluid, vaginal secretions, and
feces, there is a potential risk for transmission especially
during the second stage of labor. Thus, necessary measures
should be taken to decrease the risk of transmission during
delivery. Disinfection with ultraviolet light ≥60 min with
at least 30 min of ventilation following irradiation should
be provided after each delivery to decrease the risk of viral
transmission [4,23].
Skin-to-skin contact between the mother and the
neonate should be supported in the delivery room
providing necessary precautions like strict hand hygiene
and wearing a mask [99]. Procedures like delayed cord
clamping or cord blood banking may be performed if
necessary. Management of postpartum hemorrhage should
be performed according to current guidelines. However,
physicians should be cautious while using tranexamic
acid and methylergometrine as these drugs may aggravate
COVID-19–related complications like thrombosis and
vasoconstriction. Prophylactic-dose anticoagulation
is recommended for postpartum patients with severe/
critical COVID-19. Rooming-in should be provided and
breast feeding should be encouraged as long as necessary
precautions for viral transmission are taken [4,23,99].
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Figure. The delivery table shield used in our institution during the vaginal delivery of
suspected/confirmed cases with COVID-19.

16. Conclusion
In conclusion, the course of COVID-19 during pregnancy is
generally mild. However, SARS-CoV-2 infection in pregnant
women may rapidly progress into severe disease and
increased rates of obstetric complications are observed in
these cases. An individualized approach should be provided

by a multidisciplinary team for the management of pregnant
women with COVID-19 to achieve favorable outcomes.
Preliminary results are promising for the administration of
SARS-CoV-2 vaccines in the pregnant population. Special
protocols should be followed to prevent the transmission of
SARS-CoV-2 during the labor and delivery.
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